Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

1 in non-Hodgkin's lymphoma. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921, exercisable during a defined period. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK. GSK is expected to begin clinical trials with GSK-923295 in 2007. All of these drug candidates have arisen from Cytokinetics research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, and cardiovascular disease. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the ?Act?). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the expected initiation, timing, conduct, scope and results of Cytokinetics and its partners research and development programs, including initiation of clinical trials; anticipated dates of release of data from clinical trials; the potential benefits of Cytokinetics drug candidates and potential drug candidates, including the benefits of mitotic kinesin i
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:10/22/2014)... 2014 Influenza will affect as many as 200,000 ... the United States as high as 49,000 people.  ... is from person to person in respiratory droplets of coughs ... of death, but kills much fewer people each year than ... human fluids including sweat, saliva, blood and other bodily fluids. ...
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... , Oct. 22, 2014  Recently published clinical studies ... the already substantial database of evidence. This data has ... Stretta therapy for sufferers of refractory GERD. ... evidence supporting Stretta therapy as a safe and ... make Stretta therapy available to nearly 50 million Americans. ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
... policy , , ROCHESTER, Minn., ... use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, ... alcohol. The results of the study are published in the December ... , VIDEO ALERT: Additional audio and video ...
... VICL ) announced today the receipt of a $1.0 ... Merck,s planned initiation of a Phase I clinical trial of ... is based on Vical,s DNA gene delivery technology and encodes ... separate license agreement. , , ...
Cached Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... By Tara Haelle ... -- Binge drinking among young adult men may lead to ... binge drinking didn,t cause a similar rise in blood pressure ... study. In fact, when young adult women drank lightly or ... half, the study found. "This finding parallels studies in ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... in the war on asthma symptom control could be a ... that Mom and Dads leeriness towards their childrens asthma medications ... health risks that outweigh the benefits might explain to ... children with the wheezing, coughing and trouble-breathing disease do not ...
... Consultech Strengthens Omnicom,s Presence in China,s Growing ... ... Omnicom Group Inc.,("Omnicom") (NYSE: OMC ), the leading global ... Services,division ("DAS"), a majority ownership interest in Consultech, a leading,healthcare ...
... The American,Psychiatric Association (APA) applauds the U.S. Food and ... led to the,approval of a new treatment for two ... the approvals are a result of the federal,Best Pharmaceuticals ... that leads to this kind of approval, given that ...
... 180 day shared exclusivity on the product, ... announced today that the Company has received tentative ... manufacture and market,Galantamine Hydrobromide Tablets, 4mg (base), 8mg ... treatment of mild to moderate dementia of,the Alzheimer,s ...
... the best drug treatment for their disease, because family doctors ... in the Archives of Disease in Childhood. , Around ... disease prompts up to a third of children aged between ... researchers used national data to calculate the number of prescriptions ...
... in This Region,Deep Commitment to this Market Evidenced in Opening of ... ... and PHILADELPHIA, Sept. 3 Rohm,and Haas Company (NYSE: ROH ... in India to meet,growing demand for its environmentally advanced products and ...
Cached Medicine News:Health News:Parents' perceptions can hamper kids' asthma care, study finds 2Health News:Parents' perceptions can hamper kids' asthma care, study finds 3Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 3Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis 2Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Rohm and Haas Expands in India 2Health News:Rohm and Haas Expands in India 3Health News:Rohm and Haas Expands in India 4
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Ideal for short scleral tunnel and trabecular meshwork incisions...
30 Pre-formed and razor sharp...
Medicine Products: